To overcome these problems, researchers have turned to single-domain antibodies, also known as nanobodies. These are derived from the variable domains of heavy-chain-only antibodies (VHHs ...

These so-called nanobodies are around ten times smaller than normal antibodies. By binding to proteins, they can disrupt ...

The team’s research has shown that nanobodies – a smaller, simple form of antibody generated by llamas and camels – can effectively target the SARS-CoV-2 virus that causes Covid-19. They found that ...

Harnessing AI agents and human expertise, researchers accelerate the design of innovative nanobodies to combat evolving SARS-CoV-2 variants. Study: The Virtual Lab: AI Agents Design New SARS-CoV-2 ...

Spanish plasma-derived medicines specialist Grifols revealed it is collaborating with Dutch biotechnology start-up, FcR ...

Her writing has also appeared in The Philadelphia Inquirer, Popular Science, PBS NOVA, and more. View Full Profile. Learn about our Editorial Policies. We primarily work with nanobodies, although we ...

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with biotechnology startup FcR Therapeutics to develop recombinant nanobodies ...